Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Acute Lymphoblastic Leukemia in Children.

Next Previous
X
Search
Trial Profile

Treatment of Acute Lymphoblastic Leukemia in Children.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegaspargase (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexrazoxane; Doxorubicin; Etoposide; Folinic acid; Hydrocortisone; Mercaptopurine; Methotrexate; Methotrexate; Methylprednisolone; Prednisolone; Prednisone; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Registrational
  • Sponsors Enzon Pharmaceuticals

    • Most Recent Events

    • 14 Dec 2021 Results from trials (DFCI 05-001) or (DFCI 11-001) assessing impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 07 Nov 2019 Status changed from active, no longer recruiting to completed.
    • 07 Nov 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top